1JA Stock Overview
A commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Jaguar Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.56 |
| 52 Week High | US$36.60 |
| 52 Week Low | US$2.55 |
| Beta | 0.69 |
| 11 Month Change | 0% |
| 3 Month Change | 99.68% |
| 1 Year Change | -71.36% |
| 33 Year Change | -99.96% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1JA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -0.1% |
| 1Y | -71.4% | -19.7% | 2.4% |
Return vs Industry: 1JA underperformed the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: 1JA underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| 1JA volatility | |
|---|---|
| 1JA Average Weekly Movement | 41.9% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1JA's share price has been volatile over the past 3 months.
Volatility Over Time: 1JA's weekly volatility has increased from 35% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 49 | Lisa Conte | jaguar.health |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Jaguar Health, Inc. Fundamentals Summary
| 1JA fundamental statistics | |
|---|---|
| Market cap | €17.12m |
| Earnings (TTM) | -€35.69m |
| Revenue (TTM) | €9.44m |
1.8x
P/S Ratio-0.5x
P/E RatioIs 1JA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1JA income statement (TTM) | |
|---|---|
| Revenue | US$10.14m |
| Cost of Revenue | US$2.12m |
| Gross Profit | US$8.02m |
| Other Expenses | US$46.34m |
| Earnings | -US$38.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.25 |
| Gross Margin | 79.07% |
| Net Profit Margin | -377.95% |
| Debt/Equity Ratio | 224.5% |
How did 1JA perform over the long term?
See historical performance and comparison